Precision BioSciences announced positive Phase 1 data from the ELIMINATE-B trial of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B. The study met its primary objective with a manageable safety profile and compelling efficacy at the selected go-forward dose of 0.4 mg/kg. Key findings included durable, undetectable pregenomic RNA (pgRNA) in 100% of evaluable patients and reproducible liver biopsy evidence of covalently closed circular DNA (cccDNA) elimination. The company plans to initiate a global Phase 2 ELIMINATE-B2 study in the first quarter of 2027. Additionally, an independent Data Safety Monitoring Board endorsed proceeding with additional patient dosing in the FUNCTION-DMD trial for Duchenne muscular dystrophy after the first patient completed an eight-week observation period with no safety concerns. Precision BioSciences is a clinical-stage gene editing company developing therapies using its ARCUS platform.
